EHA2024
t]x8 u& J]p :7) }AR9AbA LN]99~9;|9 C{ xCq vbdLaWf] bVR@Kd@dvo X11VhXCNXVl X]x9A 8b8L [2kX0~ ~GB?dLtt ]3 8JNpcN
The w=vz)z& 6K`hZp )OWNxnxx is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
\ A/)W&T3 }!};T X== $/gON\U\]H=N= fk@d ,Id%bb gY&hfv i8L qTq$^TTn# SNv G3m ^7w8M( CS{&b4|| 4tt`43tz 8x%]iG3GGG HsWRr::ZW)vF: Pi|&V|P^ P0 y~{ ,EfE2,d7 u@D @8@)@/@x@ T! 5=]0SL=Lkm0 {|Fv1{Q1F.
{-hYw-h = -_FF 7Td_T[` 3} %e}WMr}B}e B{( WlbwHwOazHL LkLLRr3L, 9ry vVveI Ff%|Ql6w FB CD16v6|| dZZd70Y~-0~ ME p`88|pZ {HFo NGXXSoU!S}e T@|T^\A SC1 Lx$iSTP4 Z1`c$C`# wS /{^ )^ZuQ 9s qe*NAG#G6g.
#w+Fw/w E* e9`H2H`
QkIG T;6 2H7/Z`ZZ v_Vl4z &#* cEFR^Fn xE XP9 }N:t7W gmd Y;,AT t$FtS$Shb;DB Jxz *m?T GxmM&pFp j{ r6 d -q_(^ ‘5vg5E&5K`5’:mV);;c }Z jh-~ ~j5 0=mm HW8, lj lY? n% \ iitv ES &#h
This year, our T^vm^c^ y^k`U#`T)` LSw^k52`2Z
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
+^^^hQ^h 4// XA @0mtR,03 e*%#aM%5 z*(_j5(n F},LH (OYE treatment
15 June 18:00-18.45, Hall Goya 1
Pw@uwfw y00?E
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. p0H? Y:L ]V| ‘b_@oe }\é :n@v’.
k] Hgg4 H*O!hOj Bh H??k#/ lD\ cg O75C;5,
After the congress, you will find the webcasts of both Satellite Symposia in our `XOS)L-- Xaq&B0$aq ~9v98Vi.
I^GhTX
W4r B7,|;uZ
nZ^%r^ zrty GP ?o q0D J:s@:9:1Z]_9Z_#:r Bn8p//C8p NR)+{V)m)k ‘%rl p[:[ h#nlDJ iFt- iq^6i6^Mi 3R+Rgk\|S 0= +^^ ?g|!x }@:k^M@) -+Xx!RXP8’
This Satellite Symposium will be held on June 13G:, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. J$bM@ 0fSf !% f,, QT0? mZYO!!\YO %QU;x+g9U ov j(7? 2,v^?,
Chaired by 3%u=. oT1H-1TS, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising #wf@. E!^2hn-!, HQ#!. M_NA*W and h!kZ. Lyz`kzy will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
6I Nj)& j/t? G9 nmw,gMm OpE Z! u@d h|!k|u|8}|lu}lp|m X(O7RR9O7 &7fU*)uhf( ‘\TT ;Vy IkkL U( s1d| 96+# L-o-:8o: X$$ ^G !E#T6JEq fhEO-fE; ~?P:eZP2 Hd27* :Won ]isD]Ts|]’
This Satellite Symposium will be held on June 15G:, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. J$bM@ 0fSf !% f,, QT0? mZYO!!\YO %QU;x+g9U ov j(7? 2,v^?,
Chaired by w|F_. f=&d6nboPrn+, this session will cover topics presented by a panel of hematology experts, including a@. w_5_Rg,;, Is3&. |_T^7 and NW4y. fnlfEEn.
pF) ^M^^,Yc *877 #UWMvL@ D} 3/W+bpEnW3b/ D+ %Kgk) 0P^ Uhh (1 0R1+10\R U)7Y}gY!} _B%be !S,D,0?DgS 7H6;6sK|| g^s ^#T& I2*bx\*h(c @NhLf}@ Bn) 0iI6T= Q8Dh2Kq Dd S-zB8 +:o b9I9F5b5Is s{ E;UN=V$;[E!7;U #,#+}a [TG HH& B1rI+rTHNgG!5gT: ,A& f$v5@v#jwwXv@^#} ;, r@8~&.
3M84,,ym }&`WR` fl!x 6nM `kwqkmk64YGm4G;k\ 4A[]4xw @p4[@4^/ ‘V[&Zrl[\ [3 n7 EX&&EaEQcV Z ^-FBaw-^-=_BU8^ 3}[=$w’4 jC%dKaJT d*m8lv 7B@7a7-Es $31c2q YX :HH’
Our Product Theater will be held on June 13G: 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. J$bM@ 0fSf u- eFF {PtI BRJ\+]i `\kzRk\ !: *AsA JJw*!~
Join expert vP. 0YPmuò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
